We sequentially excluded 31 224 people with type 1 diabetes (5.1%), 748 (0.1%) without a Townsend deprivation score, and 99 745 prescribed glitazones, gliptins, or insulin in the 12 months before the study entry date, leaving 469 688 patients with type 2 diabetes in the study cohort. Here, INS is linked to type 2 diabetes mellitus.